These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35781186)

  • 1. The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.
    Kolb M; Orfanos SE; Lambers C; Flaherty K; Masters A; Lancaster L; Silverstein A; Nathan SD
    Adv Ther; 2022 Sep; 39(9):3881-3895. PubMed ID: 35781186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
    Nathan SD; Waxman A; Rajagopal S; Case A; Johri S; DuBrock H; De La Zerda DJ; Sahay S; King C; Melendres-Groves L; Smith P; Shen E; Edwards LD; Nelsen A; Tapson VF
    Lancet Respir Med; 2021 Nov; 9(11):1266-1274. PubMed ID: 34214475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.
    Corboz MR; Zhang J; LaSala D; DiPetrillo K; Li Z; Malinin V; Brower J; Kuehl PJ; Barrett TE; Perkins WR; Chapman RW
    Pulm Pharmacol Ther; 2018 Apr; 49():95-103. PubMed ID: 29408757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts.
    Ali FY; Egan K; FitzGerald GA; Desvergne B; Wahli W; Bishop-Bailey D; Warner TD; Mitchell JA
    Am J Respir Cell Mol Biol; 2006 Feb; 34(2):242-6. PubMed ID: 16239641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
    Whittle BJ; Silverstein AM; Mottola DM; Clapp LH
    Biochem Pharmacol; 2012 Jul; 84(1):68-75. PubMed ID: 22480736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.
    Nathan SD; Tapson VF; Elwing J; Rischard F; Mehta J; Shapiro S; Shen E; Deng C; Smith P; Waxman A
    Am J Respir Crit Care Med; 2022 Jan; 205(2):198-207. PubMed ID: 34767495
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells.
    Patel JA; Shen L; Hall SM; Benyahia C; Norel X; McAnulty RJ; Moledina S; Silverstein AM; Whittle BJ; Clapp LH
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality.
    Nathan SD; Johri S; Joly JM; King CS; Raina A; McEvoy CA; Lee D; Shen E; Smith P; Deng C; Waxman AB
    Thorax; 2024 Mar; 79(4):301-306. PubMed ID: 37979971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.
    Clapp LH; Gurung R
    Prostaglandins Other Lipid Mediat; 2015 Jul; 120():56-71. PubMed ID: 25917921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
    Waxman A; Restrepo-Jaramillo R; Thenappan T; Ravichandran A; Engel P; Bajwa A; Allen R; Feldman J; Argula R; Smith P; Rollins K; Deng C; Peterson L; Bell H; Tapson V; Nathan SD
    N Engl J Med; 2021 Jan; 384(4):325-334. PubMed ID: 33440084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IPF-Fibroblast Erk1/2 Activity Is Independent from microRNA Cluster 17-92 but Can Be Inhibited by Treprostinil through DUSP1.
    Blumer S; Fang L; Chen WC; Khan P; Hostettler K; Tamm M; Roth M; Lambers C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plain language summary of the INCREASE study: inhaled treprostinil (Tyvaso) for the treatment of pulmonary hypertension due to interstitial lung disease.
    West N; Smoot K; Patzlaff N; Miceli M; Waxman A
    Future Cardiol; 2023 Apr; 19(5):229-239. PubMed ID: 37466095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation.
    Lambers C; Roth M; Jaksch P; Muraközy G; Tamm M; Klepetko W; Ghanim B; Zhao F
    Sci Rep; 2018 Jan; 8(1):1087. PubMed ID: 29348469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled treprostinil: a therapeutic review.
    Channick RN; Voswinckel R; Rubin LJ
    Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Second-Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model.
    Dwyer-Nield L; Hickey GA; Friedman M; Choo K; McArthur DG; Tennis MA; New ML; Geraci M; Keith RL
    Cancer Prev Res (Phila); 2017 Nov; 10(11):671-679. PubMed ID: 28851689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts.
    Corboz MR; Salvail W; Gagnon S; LaSala D; Laurent CE; Salvail D; Chen KJ; Cipolla D; Perkins WR; Chapman RW
    Prostaglandins Other Lipid Mediat; 2021 Feb; 152():106486. PubMed ID: 33011365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis.
    Nathan SD; Behr J; Cottin V; Lancaster L; Smith P; Deng CQ; Pearce N; Bell H; Peterson L; Flaherty KR
    BMJ Open Respir Res; 2022 Jul; 9(1):. PubMed ID: 35787522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treprostinil for pulmonary hypertension.
    Skoro-Sajer N; Lang I; Naeije R
    Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
    Waxman A; Restrepo-Jaramillo R; Thenappan T; Engel P; Bajwa A; Ravichandran A; Feldman J; Hajari Case A; Argula RG; Tapson V; Smith P; Deng C; Shen E; Nathan SD
    Eur Respir J; 2023 Jun; 61(6):. PubMed ID: 37080567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.